KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Boston Scientific (BSX) Revenue (2016 - 2025)

Boston Scientific (BSX) has disclosed Revenue for 17 consecutive years, with $5.3 billion as the latest value for Q4 2025.

  • Quarterly Revenue rose 15.9% to $5.3 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $20.1 billion through Dec 2025, up 19.88% year-over-year, with the annual reading at $20.1 billion for FY2025, 19.87% up from the prior year.
  • Revenue hit $5.3 billion in Q4 2025 for Boston Scientific, up from $5.1 billion in the prior quarter.
  • In the past five years, Revenue ranged from a high of $5.3 billion in Q4 2025 to a low of $2.8 billion in Q1 2021.
  • Historically, Revenue has averaged $3.8 billion across 5 years, with a median of $3.6 billion in 2023.
  • Biggest five-year swings in Revenue: soared 53.62% in 2021 and later rose 3.68% in 2022.
  • Year by year, Revenue stood at $3.1 billion in 2021, then grew by 3.68% to $3.2 billion in 2022, then increased by 14.9% to $3.7 billion in 2023, then rose by 22.44% to $4.6 billion in 2024, then grew by 15.9% to $5.3 billion in 2025.
  • Business Quant data shows Revenue for BSX at $5.3 billion in Q4 2025, $5.1 billion in Q3 2025, and $5.1 billion in Q2 2025.